Osimertinib mesylate is a Small Molecule owned by AstraZeneca, and is involved in 143 clinical trials, of which 62 were completed, 72 are ongoing, and 9 are planned.
Osimertinib mesylate is a highly selective and irreversible inhibitor of activating sensitising EGFR mutation (EGFRm+) and activating resistance mutation T790M without affecting the activity of wild type EGFR. Inhibition of phosphorylation of EGFR and downstream signaling leads to tumor growth inhibition and it also induces cell cycle arrest.
The revenue for Osimertinib mesylate is expected to reach a total of $110.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Osimertinib mesylate NPV Report.
Osimertinib mesylate is originated and owned by AstraZeneca.
Osimertinib mesylate Overview
Osimertinib mesylate (AZD-9291 / Tagrisso) acts as an antineoplastic agent. It is formulated as film coated tablets, coated tablets and tablets for oral route of administration. Tagrisso is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) that is resistant to EGFR tyrosine kinase inhibitor (TKI) therapy, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy and for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, (exon-19 deletions or exon-21 L858R mutations). Tagrisso is indicated for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery.
It is under development for the treatment of solid tumor like non-small cell lung cancer in combination with chemotherapy, recurrent glioblastoma and leptomeningeal disease.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.
Quick View – Osimertinib mesylate
|Highest Development Stage|